tbuckley/cabot-search huggingface dataset:
Frequency and Risk Factors of Cord Graft Failure (CGF) Following Reduced Intensity Conditioning Haplo-Cord Hematopoietic Stem Cell Transplantation
Authors: Stephanie B. Tsai, Hongtao Liu, Tsiporah B. Shore, Michael R Bishop, Melissa M. Cushing, Yun Fan, Usama Gergis, Lucy A Godley, Justin Kline, Richard A. Larson, Guadalupe G. Martinez, Sebastian Mayer, Olatoyosi Odenike, Wendy Stock, Amittha Wickrema, Koen van Besien, Andrew S. Artz
Journal: Blood (2014)
Annals Story Slam - Being Out
Authors: Jill Tinmouth
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - Being OutFREEJill Tinmouth, MD, PhDJill Tinmouth, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0024 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Being Out "Being Out," by Jill Tinmouth, MD, PhD (Duration 6:42)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency
Authors: Kathryn Addonizio, Hanny Al-Samkari, Bertil Glader, D Holmes Morton, Satheesh Chonat, Alexis A. Thompson, Kevin H. M. Kuo, Yaddanapudi Ravindranath, Heng Wang, Jennifer A. Rothman, Janet L. Kwiatkowski, Charles Kung, Penelope A. Kosinski, Hasan Al-Sayegh, Wendy B. London, Rachael F. Grace
Journal: Blood (2019)
Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Authors: John McKay, Taha Al-Juhaishi, Lai Guanhua, Maciej Kmieciak, Roy Sabo, Ariel Sindel, Victor Yazbeck
Journal: Blood (2019)
Bax inhibitor 1 preserves mitochondrial homeostasis in acute kidney injury through promoting mitochondrial retention of PHB2
Authors: Jin Wang, Pingjun Zhu, Ruibing Li, Jun Ren, Yingmei Zhang, Hao Zhou
Journal: Theranostics (2019)

Bax inhibitor-1 (BI1) conveys anti-apoptotic signals for mitochondria while prohibitin 2 (PHB2) is implicated in sustaining mitochondrial morphology and function. However, their regulatory roles in acute kidney injury (AKI) are largely unknown. Methods: In human patients with AKI, levels of BI1 in urine and plasma were determined using ELISA. An experimental model of AKI was established using ATP depletion-mediated metabolic stress and ischemia-reperfusion injury (IRI) in primary tubule cells and BI1 transgenic mice, respectively. Western blots, ELISA, qPCR, immunofluorescence, RNA silencing, and domain deletion assay were employed to evaluate the roles of BI1 and PHB2 in the preservation of mitochondrial integrity. Results: Levels of BI1 in urine and plasma were decreased in patients with AKI and its expression correlated inversely with renal function. However, reconstitution of BI1 in a murine AKI model was capable of alleviating renal failure, inflammation and tubular death. Further molecular scrutiny revealed that BI1 preserved mitochondrial genetic integrity, reduced mitochondrial oxidative stress, promoted mitochondrial respiration, inhibited excessive mitochondrial fission, improved mitophagy and suppressed mitochondrial apoptosis. Intriguingly, levels of the mitochondria-localized PHB2 were sustained by BI1 and knockdown of PHB2 abolished the mitochondrial- and renal- protective properties of BI1. Furthermore, BI1 promoted PHB2 retention within mitochondria through direct interaction with cytoplasmic PHB2 to facilitate its mitochondrial import. This was confirmed by the observation that the C-terminus of BI1 and the PHB domain of PHB2 were required for the BI1-PHB2 cross-linking. Conclusion: Our data have unveiled an essential role of BI1 as a master regulator of renal tubule function through sustaining mitochondrial localization of PHB2, revealing novel therapeutic promises against AKI.
ACTR-17. DIAGNOSTIC UTILITY OF SERUM microRNA CLASSIFICATION IN DIFFUSE GLIOMA
Authors: Makoto Ohno, Juntaro Matsuzaki, Junpei Kawauchi, Yoshiaki Aoki, Junichiro Miura, Satoko Takizawa, Ken Kato, Hiromi Sakamoto, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Koichi Ichimura, Yoshitaka Narita, Takahiro Ochiya
Journal: Neuro-Oncology (2019)

Abstract To improve clinical outcomes, a less invasive screening test for detection of diffuse glioma is needed. The purpose of this study is to establish models using serum microRNAs (miRNAs) to distinguish between diffuse glioma patients from non-cancer controls (Glioma Index) and between glioblastoma (GBM), primary central nervous system lymphoma (PCNSL), and metastatic brain tumors (Meta) (3-Tumor Index). A total of 580 patients, including 266 with brain or spinal tumors and 314 non-cancer controls, were analyzed. Non-cancer control samples were collected from the National Cancer Center Biobank and members of the general population undergoing routine health examinations. Expression of serum 2565 miRNAs was assessed in each sample, and the expression profiles were compared between diffuse glioma patients and non-cancer controls, and between GBM, PCNSL, and Meta. Diagnostic models were established using a training set, and diagnostic performance was confirmed in validation and exploratory sets and area under the receiver operating curve (AUC), sensitivity, specificity, and accuracy were used to evaluate their diagnostic performances. The Glioma Index was constructed using three miRNAs. The AUC was 99%, with sensitivity of 95% and specificity of 97% in the validation set. The Glioma Index classified 93% of PCNSL, 89% of Meta, 91% of benign brain tumors, and 0% of spinal tumors as positive in the exploratory set. The 3-Tumor Index was constructed using 48 miRNAs and had an accuracy of 0.80 in the validation set, positively detecting 94.1% of GBM, 80% of Meta, and 50% of PCNSL. In conclusion, we developed novel serum miRNA discriminant models to detect diffuse glioma from non-cancer control and to discriminate tumor histology. These models could serve as less invasive screening tools or complementary diagnostic tools, thereby decreasing neurosurgical risks.
Natural language processing of electronic health records is superior to billing codes to identify symptom burden in hemodialysis patients
Authors: Lili Chan, Kelly Beers, Amy A. Yau, Kinsuk Chauhan, Áine Duffy, Kumardeep Chaudhary, Neha Debnath, Aparna Saha, Pattharawin Pattharanitima, Judy Cho, Peter Kotanko, Alex Federman, Steven G. Coca, Tielman Van Vleck, Girish N. Nadkarni
Journal: Kidney International (2019)
Loop Ileostomy a Viable Alternative for <i>Clostridium difficile</i> Colitis?
Authors: Yoshiaki Kanemoto, Tomohiro Kurokawa, Tetsuya Tanimoto
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
DDIS-35. RelA-ACTIVITY IS ESSENTIAL FOR CANNABIDIOL-MEDIATED CYTOTOXICITY IN AN IDENTIFIED SUBSET OF GLIOBLASTOMA
Authors: Marie Volmar, Bernhard Nagl, Alisha Haug, Sven Richter, Haithanm Alenezi, Christel Herold-Mende, Katrin Lamszus, Michael Synowitz, Joel Schick, Roland Kälin, Rainer Glass
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) therapy could strongly profit from simplified procedures for personalized medicine. Cannabidiol (CBD) is explored for GBM-patients, but the mode of drug-action is largely unknown and stratification markers are missing. We investigated CBD-induced cytotoxicity in a panel of human primary GBM cells as well as transgenic mouse gliomas and in different orthotopic or transgenic in vivo models. We observed therapeutic efficiency of CBD in a subset of GBM, obtained genetic markers indicating CBD-sensitive GBM and found that the p53 status segregated cell-death modes. Genome wide loss of function screening, transcription factor binding studies and knockout-models indicated a central for role for NFkB (RelA) in CBD-initiated GBM-death. CBD mediated nuclear import of RelA lacking an essential post-translational modification and reduced RelA-activity. CBD altered redox levels specifically in drug-sensitive GBM and ROS-levels in unstimulated GBM predicted therapeutic response. Hence, quantifying ROS in GBM represents a simple bioassay to identify individuals potentially profiting from CBD-application in neurooncology.
CBMT-41. IMAGING A HALLMARK OF CANCER: HYPERPOLARIZED 13C-MAGNETIC RESONANCE SPECTROSCOPY CAN NON-INVASIVELY MONITOR TERT EXPRESSION IN LOW-GRADE GLIOMAS IN VIVO
Authors: Pavithra Viswanath, Georgios Batsios, Anne Marie Gillespie, Russell O Pieper, Sabrina Ronen
Journal: Neuro-Oncology (2019)

Abstract Telomerase reverse transcriptase (TERT) expression is a hallmark of cancer, including in primary glioblastomas and low-grade oligodendrogliomas. Since TERT is essential for glioma proliferation and is an attractive therapeutic target, metabolic imaging of TERT status can inform on tumor progression and response to therapy. To that end, the goal of this study was to identify non-invasive, translational, hyperpolarized 13C-magnetic resonance spectroscopy-detectable metabolic imaging biomarkers of TERT in low-grade oligodendrogliomas. Unbiased metabolomic analysis of immortalized normal human astrocytes without (NHAcontrol) and with TERT (NHAtert) indicated that TERT induced unique metabolic reprogramming. Notably, TERT increased NADPH and NADH levels. Glucose flux through the pentose phosphate pathway (PPP) is a major producer of NADPH. Non-invasive imaging of PPP flux using hyperpolarized [U-13C,U-2H]-glucose indicated that production of the PPP metabolite 6-phosphogluconate (6-PG) was elevated in NHAtert cells relative to NHAcontrol. Importantly, hyperpolarized [U-13C,U-2H]-glucose flux to 6-PG clearly differentiated tumor from normal brain in orthotopic NHAtert tumor xenografts. Next, we exploited the observation that TERT expression increased NADH, which is essential for the metabolism of hyperpolarized [1-13C]-alanine to lactate. Lactate production from hyperpolarized [1-13C]-alanine was higher in NHAtert cells relative to NHAcontrol. Importantly, hyperpolarized [1-13C]-alanine imaging in orthotopic NHAtert tumors revealed pronounced differences in lactate production between tumor tissue and normal brain. Mechanistically, TERT increased expression of glucose-6-phosphate dehydrogenase (G6PDH), the rate-limiting enzyme for 6-PG and NADPH production, and of nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme for NADH biosynthesis. Silencing TERT reversed G6PDH and NAMPT expression and normalized hyperpolarized [U-13C,U-2H]-glucose and [1-13C]-alanine metabolism, validating our imaging biomarkers. Finally, hyperpolarized [U-13C,U-2H]-glucose and [1-13C]-alanine could monitor TERT status in the clinically relevant, patient-derived BT54 oligodendroglioma model. In summary, we demonstrate, for the first time, non-invasive in vivo imaging of TERT status in gliomas that can enable longitudinal analysis of tumor burden and treatment response in the clinic.
New approach needed to tackle drugs deaths, say MPs
Authors: Bryan Christie
Journal: BMJ (2019)

Pressure is increasing for a radical change to UK drug policy that focuses on harm reduction rather than criminalisation.

A report from the UK parliament’s Scottish Affairs Committee recommends the decriminalisation of small amounts of drugs for personal use and the introduction of legislation to allow the establishment of safe consumption facilities where users can inject drugs under medical supervision.1

It comes just two weeks after the parliament’s Health and Social Care Committee called for similar radical change in response to what it described as a “public health emergency.”2 Drug related deaths are at an all time high throughout Britain, …
Distinctive Magnetic Resonance Imaging Findings in IgLON5 Antibody Disease
Authors: Han Chen, Jinze Wu, Sarosh R. Irani
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allotransplant Using Purine Analogue/Busulfan-Based Conditioning Regimen
Authors: Maxime Jullien, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Camille Debord, Beatrice Mahe, Viviane Dubruille, Soraya Wuilleme, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Benoit Tessoulin, Yannick Le Bris, Marion Eveillard, Alix Duquesne, Philippe Moreau, Steven Le Gouill, Marie-Christine Bene, Patrice Chevallier
Journal: Blood (2019)
Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Authors: Cem Akin, Vito Sabato, Jason Gotlib, Mariana Castells, Michael W. Deininger, Hanneke Oude Elberink, Mark L Heaney, Paul van Daele, Deepti Radia, Massimo Triggiani, Daniel J. DeAngelo, Iván Alvarez-Twose, Sigurd Broesby-Olsen, Tracy I. George, Karin Hartmann, Siebenhaar Frank, Andreas Reiter, Peter Vadas, Patrizia Bonadonna, Jens P. Panse, Petra Staubach-Renz, Knut Brockow, Diamant Thaci, Hui-Min Lin, Andrew Morrison, Brenton Mar, Marcus Maurer
Journal: Blood (2019)
Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)
Authors: Amer M. Zeidan, Cynthia Z. Qi, Bhavik J. Pandya, Andy Garnham, Hongbo Yang, Manasee V Shah
Journal: Blood (2019)
Differential Expression of CD49f Discriminates the Independently Emerged Hematopoietic Stem Cells and Erythroid-Biased Progenitors
Authors: Ai-Ning Xu, Dan Liu, Yu-Ting Dai, Fan Zhang, Jian Shen, Cheng-Long Hu, Chun-Hui Xu, Yuan-Liang Zhang, Yin-Yin Xie, Qiu-Hua Huang, Peng-Fei Xu, Lan Wang, Lin Cheng, Jinyan Huang, Zhu Chen, Sai-Juan Chen, Xiao-Jian Sun
Journal: Blood (2019)
NIMG-14. THE RELATION BETWEEN T2-FLAIR MISMATCH SIGN AND ADC VALUES REFLECTING PATHOLOGICAL MICROSTRUCTURE IN LOWER-GRADE GLIOMAS
Authors: Yuichi Fujita, Takashi Sasayama, Hiroaki Nagashima, Kazuhiro Tanaka, Mitsuru Hashigutchi, Eiji Kohmura
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Although the recent studies have identified “T2-FLAIR mismatch sign” specific to IDH-mutant and 1p/19q-intact gliomas, it is unclear what the mismatch sign represents. We aimed to investigate the mechanisms and validate the clinical utility. METHODS We identified 79 lower-grade gliomas treated at Kobe University Hospital, and classified into three groups: (i) LGGIDH(m),1p19q(-) (n = 18): IDH-mutant and 1p/19q-intact, (ii) LGGIDH(m),1p19q(+) (n=26): IDH-mutant and 1p/19q co-deleted, (iii) LGGIDH(w) (n=35): IDH wild-type. We retrospectively analyzed the relation with apparent diffusion coefficient (ADC) values, metabolites in magnetic resonance spectroscopy and pathological features, and examined the influence of the presence of the mismatch sign on progression-free survival (PFS) and overall survival in LGGIDH(m),1p19q(-). RESULTS Compared to the rim presenting hyperintense on T2WI and FLAIR, the core presenting hyperintense on T2WI and reversely hypointense on FLAIR had significantly higher ADC values (p = 0.002). The core/rim ratios of ADC values were significantly higher in the cases with the mismatch sign (p = 0.001), not depending on IDH status, 1p/19q status and WHO grade. There was no significant difference in metabolites changing between the presence and absence of the mismatch sign. The cases with the mismatch sign in LGGIDH(m),1p19q(-) had abundant microcysts as a pathological feature, and longer PFS than those without the mismatch sign (5-yr PFS: 100% vs 37.5%). Multivariate analysis found the mismatch sign to be the only significant predictor for preferable PFS in LGGIDH(m),1p19q(-) (p = 0.044). CONCLUSION Our study provided the new evidence that the T2-FLAIR mismatch sign had the significantly different ADC values between the core and the rim, suggesting that the mismatch sign reflected the difference of the tumor cellularity and the microenvironment.
Carcinoma of the Colon and Rectum
Authors: James W. Jameson, Clinton R. Mullins
Journal: New England Journal of Medicine (1947)

THE purpose of this presentation is to give our experience with all the cases of carcinoma of the colon and rectum that have come under our observation from September, 1936, to September, 1946. This experience seems to be of interest since few reports from such small communities as ours (with a population of about 28,000) are forthcoming.We have tried to follow the most generally accepted methods of management as judged from past experience, observation of procedures in use elsewhere and a study of current literature for improvements in technic and care. We have also attempted to emphasize the importance . . .
Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies
Authors: Leah Fung, Aparajita Hoskote Chourasia, Eduardo Torres, Imelda Lam, Paul Erdman, David Hecht, Robert Sullivan, Brooke McElwee, Normand Richard, Avanthika Venkatachalam, Irit Snir-Alkalay, Kyle WH Chan, Frank Mercurio, Yinon Ben-Neriah, David I Stirling
Journal: Blood (2019)
Dynamics and prognostic value of the hypothalamus–pituitary–adrenal axis responses to pediatric critical illness and association with corticosteroid treatment: a prospective observational study
Authors: An Jacobs, Inge Derese, Sarah Vander Perre, Pieter J. Wouters, Sascha Verbruggen, Jaak Billen, Pieter Vermeersch, Gonzalo Garcia Guerra, Koen Joosten, Ilse Vanhorebeek, Greet Van den Berghe
Journal: Intensive Care Medicine (2019)

Increased systemic cortisol availability during adult critical illness is determined by reduced binding-proteins and suppressed breakdown rather than elevated ACTH. Dynamics, drivers and prognostic value of hypercortisolism during pediatric critical illness remain scarcely investigated.This preplanned secondary analysis of the PEPaNIC-RCT (N = 1440), after excluding 420 children treated with corticosteroids before PICU-admission, documented (a) plasma ACTH, (free)cortisol and cortisol-metabolism at PICU-admission, day-3 and last PICU-day, their prognostic value, and impact of withholding early parenteral nutrition (PN), (b) the association between corticosteroid-treatment and these hormones, and (c) the association between corticosteroid-treatment and outcome.ACTH was normal upon PICU-admission and low thereafter (p ≤ 0.0004). Total and free cortisol were only elevated upon PICU-admission (p ≤ 0.0003) and thereafter became normal despite low binding-proteins (p < 0.0001) and persistently suppressed cortisol-metabolism (p ≤ 0.03). Withholding early-PN did not affect this phenotype. On PICU-day-3, high free cortisol and low ACTH independently predicted worse outcome (p ≤ 0.003). Also, corticosteroid-treatment initiated in PICU, which further suppressed ACTH (p < 0.0001), was independently associated with poor outcomes (earlier live PICU-discharge: p < 0.0001, 90-day mortality: p = 0.02).In critically ill children, systemic cortisol availability is elevated only transiently, much lower than in adults, and not driven by elevated ACTH. Further ACTH lowering by corticosteroid-treatment indicates active feedback inhibition at pituitary level. Beyond PICU-admission-day, low ACTH and high cortisol, and corticosteroid-treatment, predicted poor outcome. This suggests that exogenously increasing cortisol availability during acute critical illness in children may be inappropriate. Future studies on corticosteroid-treatment in critically ill children should plan safety analyses, as harm may be possible.
GENE-19. TARGETED SEQUENCING PANEL (TODAI ONCOPANEL) FOR VARIOUS TYPES OF BRAIN TUMORS
Authors: Shunsaku Takayanagi, Shota Tanaka, Satoru Miyawaki, Masahiro Shin, Hirofumi Nakatomi, Aya Shinozaki-Ushiku, Kumiko Oseto, Shinji Kohsaka, Katutoshi Oda, Hiroyuki Aburatani, Hiroyuki Mano, Nobuhito Saito
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Todai OncoPanel (TOP) is a targeted sequencing panel newly invented by the University of Tokyo, which allows us to prospectively investigate on genomic abnormalities of multiple cancer-related genes. The objective of this study was to assess its role in molecular diagnosis as well as in patient treatment. METHODS Thirteen cases of brain tumors were analyzed: 10 gliomas and glioneural tumors, 2 meningiomas, and 1 intracranial sarcoma. DNA and RNA were obtained from tumor samples; DNA was obtained from peripheral blood as well. The TOP DNA panel analyzed point mutations, insertions, deletions, and copy number variations of 464 cancer-related genes. The TOP RNA panel detected fusions, exon skipping, and expression abnormalities of 463 genes. RESULTS In all cases of gliomas, the tumor content was abundantly high and the analysis was performed with sufficient depth. The IDH1/2 mutation status and chromosome 1p/19q status were completely consistent with those obtained by Sanger sequencing and microsatellite analysis. In benign brain tumors, the tumor content tended to be low. The number of gene mutations identified also tended to be low. In a case of glioneuronal tumor, FGFR2 mutation was recognized, but there was no clinical trials of FGFR inhibitors open in Japan yet. DISCUSSION TOP is useful as an aid for molecular diagnosis of gliomas. In spite of some targetable genetic abnormalities detected in the tested tumors, its efficacy may be limited by the scant availability of respective molecularly targeted agents.